Abstract
In the last 25 years, the U.S. Food and Drug Administration (FDA) approved 11 new
molecular entities (NMEs) comprising quinoline as core moiety. These drugs are primarily
used for the treatment of anemia, malaria, hepatitis, and various types of cancer,
i.e., lung, breast, kidney, blood, and thyroid. Based on their approval date, a chronological
discussion on these marketed drugs is provided. This Perspective summarizes the industrial
synthesis, mechanism of action, and clinical uses of the quinoline-based FDA-approved
NMEs of the 21st century.
1 Introduction
2 Quinoline-Based FDA-Approved Drugs
2.1 Mitapivat (2022)
2.2 Tivozanib (2021)
2.3 Capmatinib (2020)
2.4 Tafenoquine (2018)
2.5 Neratinib (2017)
2.6 Lenvatinib (2015)
2.7 Simeprevir (2013)
2.8 Bosutinib (2012)
2.9 Cabozantinib (2012)
2.10 Bedaquiline (2012)
2.11 Pitavastatin (2009)
3 Conclusion
4 Abbreviations
Key words
drugs - FDA - NMEs - quinoline
